Primary Peritoneal Cancer: What It Is and How It Relates to Ovarian Cancer
When 58-year-old Sunita started experiencing persistent abdominal bloating that made her pants feel tight, along with feeling full quickly during meals and vague pelvic discomfort, she initially blamed menopause and aging. But when the bloating worsened over several weeks and she noticed her abdomen visibly swelling, her doctor ordered an ultrasound. The scan revealed fluid in her abdomen and suspicious masses scattered throughout her peritoneum—the thin membrane lining the abdominal cavity. CT scan and biopsy confirmed primary peritoneal cancer, a rare cancer affecting only 7-10 women per million each year. Remarkably, primary peritoneal cancer behaves almost identically to ovarian cancer, shares the same genetic risk factors, affects the same age group, and is treated with the same medications—yet it arises from the peritoneal lining rather than the ovaries themselves. Understanding this cancer is crucial because women who’ve had their ovaries removed to prevent ovarian cancer can still develop primary peritoneal cancer, and early recognition of subtle symptoms can lead to earlier diagnosis when treatment is most effective.
The Peritoneum: Your Body’s Internal Protective Lining
Your peritoneum is a thin, transparent membrane measuring just two cell layers thick that lines your entire abdominal cavity and covers all your abdominal organs like a plastic wrap. It has two continuous layers working as one structure. The parietal peritoneum lines the abdominal wall—the inside surface of your belly muscles and back. The visceral peritoneum covers all your organs including stomach, intestines, liver, spleen, bladder, and in women, the uterus and ovaries. These two layers create a potential space called the peritoneal cavity containing a small amount of fluid (about 50-100 milliliters) that lubricates organs allowing them to slide smoothly against each other as you move, breathe, and digest food.
The peritoneum isn’t just passive wrapping—it’s an active organ performing important functions. It produces peritoneal fluid containing immune cells that fight infection, absorbs fluid and nutrients from the peritoneal cavity back into blood vessels, provides blood supply and lymphatic drainage to abdominal organs, and contains mesothelial cells capable of producing substances that repair damage and prevent adhesions after injury or surgery. The peritoneal surface area is enormous—roughly equivalent to your skin surface area (1.5-2 square meters)—providing vast territory where cancer can spread.
Primary peritoneal cancer arises from the mesothelial cells lining the peritoneum. These cells share a common embryonic origin with the cells lining the ovaries—both develop from the same tissue layer during fetal development called coelomic epithelium. This shared ancestry explains why primary peritoneal cancer and epithelial ovarian cancer behave almost identically, look identical under the microscope, produce the same tumor marker (CA-125), carry the same genetic mutations (BRCA1, BRCA2), and respond to the same chemotherapy drugs. In fact, many experts consider them variants of the same disease rather than separate cancers.
The key distinguishing feature is location: primary peritoneal cancer involves the peritoneal surfaces extensively with normal-sized or minimally involved ovaries, while ovarian cancer originates in the ovaries with possible peritoneal spread. However, this distinction often becomes blurred because advanced ovarian cancer spreads throughout the peritoneum, and some primary peritoneal cancers involve the ovary surfaces. The practical importance is that women who’ve undergone prophylactic oophorectomy (preventive ovary removal) to reduce cancer risk remain at risk for primary peritoneal cancer—estimated at 2-4% lifetime risk after oophorectomy compared to the general population’s 7 per million annual incidence.
Symptoms: Vague Abdominal Problems That Worsen Gradually
Primary peritoneal cancer symptoms are frustratingly non-specific, often dismissed as digestive problems, menopause, or stress until the disease becomes advanced. The most common symptoms mirror advanced ovarian cancer and include abdominal bloating or increased abdominal size—the most frequent complaint, with 80-90% of patients noticing their pants becoming tight or abdomen visibly distending. This occurs from fluid accumulation (ascites) and tumor masses growing on peritoneal surfaces. Feeling full quickly when eating (early satiety) happens because tumor and fluid fill the abdominal cavity, leaving less room for stomach expansion. Patients describe eating just a few bites before feeling uncomfortably full.
Pelvic or abdominal pain occurs in 60-70% of patients—described as constant dull aching, cramping, or pressure sensation rather than sharp severe pain. Urinary symptoms develop when tumor presses on bladder including increased frequency (needing to urinate often), urgency (sudden strong need to urinate), and difficulty emptying bladder completely. Changes in bowel habits happen as tumor affects intestines causing constipation (most common), diarrhea, or alternating between both. Patients may notice incomplete bowel movements or thin stools if intestines are partially obstructed.
Unexplained weight loss occurs paradoxically despite the abdomen enlarging—patients lose weight from arms, legs, and face while their belly grows from fluid and tumor. Fatigue and weakness develop as cancer progresses, affecting energy levels and ability to perform daily activities. Nausea, indigestion, and loss of appetite are common especially as disease advances and fluid accumulates. Shortness of breath can occur if fluid accumulates in the chest cavity (pleural effusion) or if the swollen abdomen pushes up against the diaphragm restricting lung expansion.
The challenge is that these symptoms are extremely common in the general population—bloating, constipation, urinary frequency affect millions of women without cancer. The key warning signs are persistence (symptoms continuing daily for more than 2-3 weeks without improvement), progression (symptoms gradually worsening rather than fluctuating), and new onset (symptoms starting recently in someone who didn’t previously have them). Any woman over age 50 with new persistent bloating, pelvic pain, urinary symptoms, or feeling full quickly should undergo evaluation including pelvic examination, CA-125 blood test, and imaging.
Most patients are diagnosed at advanced stages (stage III or IV) because symptoms don’t appear until the disease has spread extensively throughout the peritoneal cavity. Only 10-15% are diagnosed at stage I (confined to peritoneum) when symptoms are minimal or absent. This contrasts with many cancers where screening programs enable early detection—no effective screening exists for primary peritoneal cancer, making symptom awareness the primary means of detection.
Diagnosis: From Blood Tests to Surgery
Diagnosing primary peritoneal cancer requires combining clinical suspicion, blood tests, imaging, and ultimately surgical exploration with biopsy. When symptoms raise concern, the first test is usually CA-125—a protein produced by most peritoneal and ovarian cancers that leaks into the bloodstream. Normal CA-125 levels are below 35 units/mL, while primary peritoneal cancer patients typically have levels in the hundreds to thousands. However, CA-125 isn’t specific for cancer—it can be elevated in benign conditions including endometriosis, fibroids, ovarian cysts, pelvic inflammatory disease, liver disease, and even normal menstruation. Therefore, elevated CA-125 requires further evaluation but doesn’t confirm cancer.
Transvaginal ultrasound examines the ovaries and pelvis looking for masses, fluid, or abnormalities. In primary peritoneal cancer, the ovaries are often normal-sized or minimally enlarged—unlike ovarian cancer where large ovarian masses are typically visible. The ultrasound may show fluid in the pelvis (pelvic ascites) and peritoneal thickening or nodules. CT scan of abdomen and pelvis with intravenous and oral contrast provides comprehensive imaging showing peritoneal thickening, nodules scattered throughout the peritoneum, omental caking (the omentum—a fatty apron covering intestines—becomes infiltrated with tumor appearing thickened), ascites (fluid in abdomen), and any involvement of organs like liver, spleen, or bowel. The pattern of peritoneal thickening and nodules without dominant ovarian masses suggests primary peritoneal cancer rather than ovarian cancer.
MRI can better characterize pelvic masses and distinguish fluid from solid tumor. Chest X-ray or CT checks for pleural effusion (fluid around lungs) or lung metastases. PET/CT scan using radioactive glucose tracer lights up metabolically active cancer cells throughout the body, helping identify all disease sites and assess whether surgery might achieve complete tumor removal. Before proceeding to surgery, some patients undergo paracentesis—inserting a needle into the abdomen to withdraw fluid for analysis. The fluid is examined for cancer cells, though negative results don’t rule out cancer if clinical suspicion remains high.
Definitive diagnosis requires surgical exploration and biopsy. Most patients undergo exploratory laparotomy (opening the abdomen through an incision) or laparoscopy (minimally invasive surgery using cameras and instruments through small incisions). During surgery, the surgeon inspects all peritoneal surfaces, takes biopsies from multiple sites, examines the ovaries, removes suspicious nodules, and attempts cytoreduction (surgical removal of as much tumor as possible). The pathologist examines tissue samples determining whether it’s primary peritoneal cancer, ovarian cancer, or another diagnosis.
Distinguishing primary peritoneal cancer from metastatic ovarian cancer requires meeting specific criteria: both ovaries are normal size or minimally enlarged (not typical ovarian cancer masses), ovarian involvement is surface only or minimal, most tumor burden is on peritoneal surfaces, and microscopic examination shows cancer consistent with peritoneal or ovarian origin rather than spread from another organ. In practice, the distinction matters less than recognizing that treatment is essentially identical.
Treatment: Surgery and Chemotherapy Working Together
Treatment follows the same principles as advanced ovarian cancer—cytoreductive surgery followed by chemotherapy. The primary treatment is cytoreductive surgery (also called debulking surgery) aiming to remove all visible tumor. The surgeon performs total abdominal hysterectomy removing the uterus and cervix, bilateral salpingo-oophorectomy removing both ovaries and fallopian tubes (even if they appear normal), omentectomy removing the omentum (fatty tissue where cancer often spreads), peritoneal stripping removing tumor-involved peritoneum from various surfaces, lymph node sampling or removal checking for cancer spread, and possible bowel resection if tumor involves intestines. The goal is achieving “optimal cytoreduction”—leaving no visible tumor or residual nodules smaller than 1 centimeter. Patients with optimal cytoreduction have significantly better survival (median 3-4 years) compared to suboptimal cytoreduction with residual tumor larger than 1 cm (median 1-2 years).
After surgery, patients receive combination chemotherapy—the backbone treatment for primary peritoneal cancer. The standard regimen combines carboplatin (a platinum-based drug damaging cancer cell DNA) and paclitaxel (a taxane drug preventing cancer cells from dividing). This combination is given intravenously every 3 weeks for 6 cycles (about 18 weeks total). Response rates are 70-80%, meaning 70-80% of patients experience tumor shrinkage. An alternative delivery method is intraperitoneal (IP) chemotherapy where chemotherapy is infused directly into the abdominal cavity through a surgically placed catheter, delivering high drug concentrations directly to peritoneal surfaces where cancer grows. Studies show IP chemotherapy improves survival by 12-16 months compared to IV chemotherapy alone, though it causes more side effects including abdominal pain, infection risk, and catheter complications. Not all patients are candidates for IP chemotherapy—it requires optimal cytoreduction with minimal residual disease and good overall health.
Newer treatment approaches include bevacizumab (Avastin)—a drug blocking tumor blood vessel growth added to chemotherapy and continued as maintenance after chemotherapy completes. Studies show bevacizumab improves progression-free survival by 4-6 months. PARP inhibitors (olaparib, niraparib, rucaparib) for patients with BRCA mutations or other DNA repair defects. These drugs prevent cancer cells from repairing DNA damage, causing them to die. As maintenance therapy after chemotherapy response, PARP inhibitors dramatically improve progression-free survival—from 5-6 months without treatment to 13-19 months with treatment in BRCA-mutated patients. All patients with primary peritoneal cancer should undergo genetic testing for BRCA1 and BRCA2 mutations because finding a mutation opens treatment options and has implications for family members who might also carry mutations and benefit from increased surveillance or preventive measures.
For recurrent disease (which occurs in 70-80% of patients within 2-5 years), treatment depends on how long remission lasted. Platinum-sensitive recurrence (remission lasting more than 6 months) is treated with platinum-based combination chemotherapy again, achieving responses in 50-70%. Platinum-resistant recurrence (remission lasting less than 6 months) requires alternative drugs including pegylated liposomal doxorubicin, topotecan, gemcitabine, or paclitaxel weekly. Response rates are lower (15-30%) and duration shorter. Secondary cytoreductive surgery may be considered for selected recurrent patients with isolated tumor masses that are resectable, especially if the disease-free interval was long (over 12 months).
Prognosis and Living with Primary Peritoneal Cancer
Primary peritoneal cancer prognosis mirrors advanced ovarian cancer—both are serious diseases but treatable with potential for long-term survival in some patients. The overall 5-year survival rate is 30-40% for all stages combined. Stage-specific survival shows stage I-II (rare, only 10-15% of cases) have 60-70% 5-year survival, stage III (most common, 60-70% of cases) have 30-40% 5-year survival, and stage IV (20-30% of cases) have 15-25% 5-year survival. Factors predicting better outcomes include optimal cytoreduction achieving no visible residual tumor (most important factor), good performance status (able to perform daily activities), younger age at diagnosis, high-grade serous histology responding well to platinum chemotherapy, complete or partial response to initial chemotherapy, and BRCA mutation (paradoxically predicts better chemotherapy response and survival).
The disease course typically involves initial treatment achieving remission (tumor undetectable on scans and CA-125 normal) in 70-80% of patients, followed by recurrence in 70-80% within 2-5 years. Treatment of first recurrence achieves second remission in 50-70% lasting 8-18 months. Subsequent recurrences occur with shorter intervals between relapses and shorter remission durations. However, some patients achieve remarkably long survivals—10-20% remain disease-free 10+ years after initial treatment, and some patients live 5-10 years managing multiple recurrences with successive treatments. The disease often behaves as a chronic condition requiring ongoing monitoring and intermittent treatment rather than a rapidly fatal cancer.
Quality of life considerations are paramount. Side effects from chemotherapy including nausea, fatigue, neuropathy (numbness/tingling in hands and feet), and hair loss affect daily function. Ascites causing abdominal swelling and discomfort may require repeated paracentesis (draining fluid with needle) for symptomatic relief. Bowel obstruction from tumor affecting intestines occurs in 20-40% of advanced cases, requiring dietary modifications, medications, or procedures relieving obstruction. Pain management is crucial—many patients need narcotic pain medications, nerve blocks, or palliative radiation controlling symptoms. Emotional and psychological support through counseling, support groups, and connecting with other patients helps cope with the chronic uncertainty of living with cancer.
Frequently Asked Questions
Q1: I had my ovaries removed years ago to prevent ovarian cancer because of a BRCA mutation. Can I still get primary peritoneal cancer?
Yes, unfortunately you remain at risk for primary peritoneal cancer even after prophylactic oophorectomy (preventive ovary removal). The risk is significantly reduced compared to keeping your ovaries—studies show risk-reducing salpingo-oophorectomy decreases ovarian/peritoneal cancer risk by 80-90%, but it doesn’t eliminate risk entirely. BRCA1 mutation carriers who undergo the procedure have approximately 2-4% lifetime risk of developing primary peritoneal cancer compared to 40-60% risk of ovarian cancer if ovaries kept. BRCA2 carriers have lower residual risk around 1-2%. This residual risk exists because the peritoneum and ovary surface both originate from the same embryonic tissue (coelomic epithelium) that carries the BRCA mutation throughout. Removing the ovaries eliminates the major site where cancer typically arises but doesn’t remove all the at-risk tissue lining the abdomen. You should remain vigilant for symptoms—persistent bloating, pelvic pain, urinary symptoms, feeling full quickly—and report them promptly. Some experts recommend periodic CA-125 blood tests (every 6-12 months) after risk-reducing surgery, though evidence supporting this surveillance strategy is limited. Transvaginal ultrasound obviously can’t visualize ovaries after removal, but if symptoms develop, imaging with CT or MRI can evaluate the peritoneum. The important message is that while risk-reducing surgery dramatically lowers cancer risk and is still strongly recommended for BRCA carriers, it’s not 100% protective. Maintaining awareness and promptly reporting any concerning symptoms ensures that if primary peritoneal cancer does develop, it’s detected and treated as early as possible.
Q2: How is primary peritoneal cancer different from peritoneal mesothelioma? Are they the same thing?
No, primary peritoneal cancer and peritoneal mesothelioma are completely different diseases despite both affecting the peritoneum. Primary peritoneal cancer arises from the epithelial cells lining the peritoneum and is essentially the same disease as epithelial ovarian cancer—it’s treated with platinum-based chemotherapy and has 30-40% 5-year survival. Peritoneal mesothelioma arises from mesothelial cells (different cell type) and is caused by asbestos exposure in 80-90% of cases. Mesothelioma behaves differently, is treated with different chemotherapy drugs (pemetrexed plus cisplatin), and has worse prognosis (5-year survival 10-20%). The diseases are distinguished by pathology examination. Primary peritoneal cancer cells look like ovarian cancer cells—glandular structures, papillary formations, and positive staining for markers like CA-125, PAX8, and WT1. Mesothelioma cells have different appearance and stain positive for calretinin, D2-40, and mesothelin while negative for PAX8 and WT1. Risk factors differ completely: primary peritoneal cancer occurs in women (rarely men), is associated with BRCA mutations and family history of ovarian/breast cancer, and has no association with asbestos. Mesothelioma affects men and women equally, is strongly associated with asbestos exposure (occupational exposure in shipyards, construction, insulation work), and has no association with BRCA. If you’re diagnosed with a peritoneal tumor, confirm with your oncologist which type you have because treatment and prognosis differ substantially. The confusion arises because both involve the peritoneum and both cause ascites and peritoneal thickening on imaging, but they’re managed by different specialists using different approaches.
Q3: My mother died from ovarian cancer and I have symptoms similar to hers. Should I be tested for primary peritoneal cancer even though my ovaries look normal on ultrasound?
Absolutely yes—you should undergo thorough evaluation. Primary peritoneal cancer can occur with completely normal-appearing ovaries on ultrasound because the cancer arises from the peritoneal lining rather than the ovaries themselves. Your family history of ovarian cancer increases your risk for both ovarian and peritoneal cancer, especially if your mother carried a BRCA mutation. The evaluation should include several steps: detailed pelvic examination checking for masses, fluid, or tenderness. CA-125 blood test—elevated levels suggest possible cancer requiring further investigation. Transvaginal ultrasound examining ovaries and pelvis for masses or fluid, but remember normal ovaries don’t rule out peritoneal cancer. CT scan or MRI of abdomen and pelvis looking for peritoneal thickening, nodules, ascites, and omental involvement even if ovaries appear normal. Consider genetic counseling and BRCA testing if your mother’s BRCA status is unknown or if she tested positive. If imaging shows concerning findings (peritoneal thickening, ascites, omental involvement) even with normal ovaries, you may need exploratory surgery with biopsy for definitive diagnosis. Some women with strong family history but unclear imaging findings undergo diagnostic laparoscopy (minimally invasive exploratory surgery) to directly visualize and biopsy the peritoneum. Don’t let normal ovaries on ultrasound reassure you excessively if symptoms persist—be your own advocate, insist on thorough evaluation, and consider seeing a gynecologic oncologist (specialist in women’s cancers) who has more experience with these subtle presentations. Early detection dramatically improves outcomes, so persistent symptoms warrant aggressive investigation.
Q4: What are the side effects of intraperitoneal chemotherapy and is it worth the extra discomfort?
Intraperitoneal (IP) chemotherapy delivers chemotherapy directly into the abdominal cavity through a surgically placed catheter, exposing peritoneal surfaces to much higher drug concentrations than IV chemotherapy alone. Studies show IP chemotherapy improves survival by 12-16 months compared to IV chemotherapy only—this is a significant benefit. However, IP chemotherapy causes more side effects. Abdominal pain and cramping during and after infusions are the most common complaints—patients describe feeling bloated, pressured, or crampy as 1-2 liters of chemotherapy fluid fills the abdomen. Pain usually resolves within 24-48 hours as fluid is absorbed. Infection risk exists with the catheter—the tube entering the abdomen can become infected requiring antibiotics or catheter removal. Catheter malfunction happens in 20-40% of patients—the catheter can become blocked, kinked, or dislodged, preventing chemotherapy delivery and requiring replacement procedures. Fatigue and nausea are worse than with IV chemotherapy alone. Some patients develop bowel obstruction symptoms if chemotherapy causes inflammation. Not all patients are candidates for IP chemotherapy. Requirements include optimal cytoreduction (no tumor larger than 1 cm remaining after surgery), good kidney function, absence of significant adhesions or bowel issues, and good overall health tolerating aggressive treatment. Patients with extensive prior surgeries, bowel adhesions, or large residual tumor aren’t suitable. The decision whether IP chemotherapy is “worth it” depends on individual factors: if you’re a good candidate (optimal cytoreduction, good health), the survival benefit is substantial enough that most experts recommend it despite increased side effects. If you’re borderline eligible or have poor tolerance for side effects, IV chemotherapy alone is still effective. Discuss with your oncologist whether you’re a candidate and what side effect management strategies would be used. Many patients who complete IP chemotherapy say the survival benefit was worth the temporary discomfort.
Q5: Can primary peritoneal cancer be cured, or is it always going to come back eventually?
The honest answer is that primary peritoneal cancer is rarely cured in the traditional sense of being completely eradicated never to return, but approximately 15-20% of patients achieve long-term disease-free survival that may represent cure. The disease is best understood as having a spectrum of outcomes. Some patients (15-20%) achieve complete remission with initial treatment (surgery plus chemotherapy) and remain disease-free 10, 15, 20+ years with no evidence of recurrence—these patients may be considered cured though lifelong surveillance continues. Other patients (60-70%) achieve initial remission but experience recurrence within 2-5 years, then have a chronic relapsing-remitting course—living years to decades with cancer, experiencing multiple remissions and recurrences, receiving multiple lines of treatment over time. Some patients (10-20%) have aggressive disease resistant to initial treatment or rapid recurrence, surviving 1-3 years despite multiple treatments. Factors predicting the better outcomes (possible cure) include young age at diagnosis under 50, optimal cytoreduction leaving no visible tumor, complete response to chemotherapy (CA-125 normal, no disease on scans), BRCA mutation conferring better chemotherapy sensitivity, and stage I-II disease (though rare). The disease behavior has changed with modern treatments—median survival improved from 12-18 months in the 1980s to 3-5 years currently with platinum chemotherapy, bevacizumab, and PARP inhibitors. Some patients now live 8-10+ years managing recurrent disease as a chronic condition. Even if not “cured,” many patients have extended survival with good quality of life between treatments. The key is realistic hope—while most patients will experience recurrence, excellent treatments exist for first, second, third, and subsequent recurrences. Research continues developing better drugs, and clinical trials offer access to novel therapies potentially improving outcomes further.
Disclaimer
This article adapts publicly available information from medical databases and research organizations. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. Decisions about primary peritoneal cancer screening, diagnosis, and treatment should be made in consultation with qualified physicians, gynecologic oncologists, and genetic counselors who can evaluate your individual symptoms, family history, genetic testing results, and health circumstances. If you have persistent bloating, pelvic pain, or other concerning symptoms, please consult with your healthcare team immediately.
References
- National Cancer Institute. Primary Peritoneal Cancer Treatment. https://www.cancer.gov/types/ovarian/patient/peritoneal-treatment-pdq
- PMC. Primary Peritoneal Carcinoma: A Review of the Literature. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458817/
- American Cancer Society. What Is Primary Peritoneal Cancer? https://www.cancer.org/cancer/ovarian-cancer/about/what-is-primary-peritoneal-carcinoma.html
- PMC. Primary Peritoneal Carcinoma: Clinical Features and Management. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470812/
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
